Dr. Reddy's Laboratories Ltd marked a 5.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $15.54? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
-
Dr. Reddy's Laboratories Ltd belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19
-
The company's P/B ratio is 0.04
-
Dr. Reddy's Laboratories Ltd has a trailing 12 month Price to Earnings (P/E) ratio of 19.7 based on its trailing 12 month price to earnings (EPS) of $0.79 per share
-
Its forward P/E ratio is 17.9, based on its forward earnings per share (EPS) of $0.87
-
Over the last four years, Dr. Reddy's Laboratories Ltd has averaged free cash flows of $391.33 Million, which on average grew 9.5%
-
RDY's gross profit margins have averaged 55.0 % over the last four years and during this time they had a growth rate of 1.8 % and a coefficient of variability of 6.26 %.
-
Dr. Reddy's Laboratories Ltd has moved 4.8% over the last year compared to 11.5% for the S&P 500 -- a difference of -6.7%